β-Catenin Inhibitors Show Potent Activity Against Double-Mutant Endometrial Cancer in Preclinical Study
A new preclinical study shows that the β-catenin/CBP inhibitor ICG-001 selectively kills endometrial cancer cells carrying both PIK3CA and CTNNB1 ...
